Dosage and duration of antipsychotic treatment in demented outpatients with agitation or psychosis
The USA Food and Drug Administration (FDA) issued warnings regarding the use of antipsychotics in patients with dementia in 2003 and 2005. We aimed to study the dose and duration of antipsychotic treatment in dementia, and to examine whether physicians' prescription behaviors changed after the...
Main Authors: | Yi-Ting Lin, Tzung-Jeng Hwang, Jia-Chi Shan, Huey-Ling Chiang, Yi-Han Sheu, Hai-Gwo Hwu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-02-01
|
Series: | Journal of the Formosan Medical Association |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0929664612004378 |
Similar Items
-
Metabolic dysregulation in early onset psychiatric disorder before and after exposure to antipsychotic drugs
by: Rehmat Shah, et al. -
The Psychopharmacology of Agitation: Consensus Statement of the American Association for Emergency Psychiatry Project BETA Psychopharmacology Workgroup
by: Michael P. Wilson, et al.
Published: (2012-04-01) -
The comparative efficacy of Haloperidol (IM) plus Lorazepam (PO) and Risperidon plus Lorazepam in the management of acute agitation
by: H.Toofanei (M.D), et al.
Published: (2002-09-01) -
Is There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA Guidelines
by: Giampaolo Perna, et al.
Published: (2016-04-01) -
Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews
by: Tamara Melnik, et al.